Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DI6G5U
|
|||
| Drug Name |
KB001A
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9] | Phase 2 | [1] | |
| Infectious disease [ICD-11: 1A00-CA43.1; ICD-10: A00-B99] | Phase 2 | [2] | ||
| Company |
Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Pseudomonas PcrV protein type III (Pseudo pcrV) | Target Info | Inhibitor | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00638365) Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT01695343) Study to Evaluate the Effect of KB001-A on Time-to-Need for Antibiotic Treatment. U.S. National Institutes of Health. | |||
| REF 3 | KB001-A, a novel anti-inflammatory, found to be safe and well-tolerated in cystic fibrosis patients infected with Pseudomonas aeruginosa. J Cyst Fibros. 2018 Jul;17(4):484-491. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.